MCID: DMY004
MIFTS: 50

Demyelinating Disease

Categories: Neuronal diseases

Aliases & Classifications for Demyelinating Disease

MalaCards integrated aliases for Demyelinating Disease:

Name: Demyelinating Disease 12 74 15
Demyelinating Diseases 54 44 71
Demyelinating Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3213
MeSH 44 D003711
NCIt 50 C34527
UMLS 71 C0011303

Summaries for Demyelinating Disease

Disease Ontology : 12 A neurodegenerative disease that is characterized by damage to the myelin sheath present around nerve axons.

MalaCards based summary : Demyelinating Disease, also known as demyelinating diseases, is related to allergic encephalomyelitis and neuromyelitis optica. An important gene associated with Demyelinating Disease is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Immunoglobulins and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and brain, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 74 A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is... more...

Related Diseases for Demyelinating Disease

Diseases related to Demyelinating Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 675)
# Related Disease Score Top Affiliating Genes
1 allergic encephalomyelitis 32.5 PLP1 MOG MBP CCL2
2 neuromyelitis optica 32.3 MOG MBP IL1B IL17A IFNA1 HLA-DRB1
3 multiple sclerosis 32.0 TNF PTPRC PLP1 MPZ MOG MMP9
4 optic neuritis 31.3 TNF PLP1 MPZ MOG MBP IL1B
5 acute transverse myelitis 31.2 MMP9 AQP4
6 acute disseminated encephalomyelitis 31.2 MPZ MOG MBP IL1B IFNB1 HLA-DRB1
7 neuritis 31.2 TNF PLP1 MPZ MOG MMP9 MBP
8 progressive multifocal leukoencephalopathy 31.2 TNF MBP IFNB1 CCR6
9 autoimmune disease 31.2 TNF PLP1 MOG MMP9 MBP IL1B
10 myelitis 31.1 TNF MOG MMP9 MBP IL17A IFNB1
11 polyneuropathy 31.1 TNF MPZ MBP IL1B
12 guillain-barre syndrome 31.1 TNF MPZ MOG MBP IL17A HLA-DRB1
13 transverse myelitis 31.0 TNF MOG MMP9 MBP IL17A CCR6
14 hepatitis 31.0 TNF MMP9 IFNG IFNA1 CXCL10
15 hepatitis b 31.0 TNF IFNG IFNB1 IFNA1 HLA-DRB1
16 encephalitis 31.0 TNF PTPRC MOG IL1B IFNB1 CXCL10
17 pediatric multiple sclerosis 31.0 MOG MMP9 HLA-DRB1
18 myasthenia gravis 30.9 TNF PLP1 MBP IFNG
19 chronic inflammatory demyelinating polyradiculoneuropathy 30.8 MPZ MBP IL17A IFNG IFNB1 HLA-DRB1
20 spinal cord injury 30.8 TNF MMP9 CSPG4 AQP4
21 spondylitis 30.8 TNF IL1B IL17A IFNG CCR6
22 acute retrobulbar neuritis 30.8 MBP AQP4
23 allergic disease 30.8 TNF IL1B IFNG CXCL10 CCR6
24 quadriplegia 30.7 PLP1 MOG CCR6
25 metachromatic leukodystrophy 30.7 PTPRC PLP1 MPZ MBP
26 mumps 30.7 TNF IL1B IFNG IFNB1 IFNA1 HLA-DRB1
27 uveitis 30.7 TNF IL1B IL17A IFNG CXCL10 CCL2
28 measles 30.7 TNF IL1B IFNG IFNB1 IFNA1 HLA-DRB1
29 psoriatic arthritis 30.7 TNF IL1B IL17A IFNG HLA-DRB1 CXCL10
30 polyradiculoneuropathy 30.7 MPZ MBP IL17A IFNG
31 spondyloarthropathy 1 30.7 TNF IL17A CCR6
32 intracranial hypertension 30.7 TNF IL1B CXCL10 AQP4
33 pustulosis of palm and sole 30.6 TNF IL17A CCR6
34 acquired immunodeficiency syndrome 30.6 TNF MBP IL1B IFNG IFNA1 CCR6
35 juvenile rheumatoid arthritis 30.6 TNF IL1B IFNG HLA-DRB1 CCL2
36 rubella 30.6 TNF MOG IL1B IFNG IFNB1 HLA-DRB1
37 hydrocephalus 30.6 TNF NTF3 MBP IFNG AQP4
38 subacute sclerosing panencephalitis 30.6 TNF MOG MBP IFNG IFNA1
39 relapsing-remitting multiple sclerosis 30.5 TNF PLP1 MOG MMP9 MBP IL1B
40 covid-19 30.5 IL1B IFNB1 IFNA1 CXCL10 CCL2
41 neurosarcoidosis 30.5 TNF MOG AQP4
42 balo concentric sclerosis 30.5 MOG MBP IFNB1 AQP4
43 viral encephalitis 30.5 TNF MOG MBP IL1B IFNB1 IFNA1
44 internuclear ophthalmoplegia 30.5 MOG MBP IFNB1 AQP4
45 optic nerve disease 30.5 TNF MOG MBP IL1B IL17A IFNB1
46 retinal vein occlusion 30.5 TNF IL1B CCL2
47 iridocyclitis 30.5 TNF IL1B IL17A
48 diverticulitis 30.4 TNF MMP9 CCR6
49 psoriasis 30.4 TNF IL1B IL17A IFNG HLA-DRB1 CXCL10
50 brain edema 30.4 MMP9 IL1B IFNG AQP4

Graphical network of the top 20 diseases related to Demyelinating Disease:



Diseases related to Demyelinating Disease

Symptoms & Phenotypes for Demyelinating Disease

GenomeRNAi Phenotypes related to Demyelinating Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ABCD1 CCL2 CCR6 IL17A MOG NTF3

MGI Mouse Phenotypes related to Demyelinating Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 ABCD1 AQP4 CCR6 CSPG4 CXCL10 IFNB1
2 homeostasis/metabolism MP:0005376 10.22 ABCD1 AQP4 CCR6 CSPG4 CXCL10 IFNB1
3 immune system MP:0005387 10.19 ABCD1 AQP4 CCL2 CCR6 CSPG4 CXCL10
4 nervous system MP:0003631 10.06 ABCD1 AQP4 CCR6 CSPG4 CXCL10 IFNB1
5 no phenotypic analysis MP:0003012 9.5 AQP4 CSPG4 IFNB1 IFNG IL17A PTPRC
6 respiratory system MP:0005388 9.23 AQP4 IFNG IL17A MMP9 MPZ NTF3

Drugs & Therapeutics for Demyelinating Disease

Drugs for Demyelinating Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4
2 gamma-Globulins Phase 4
3 Immunoglobulins, Intravenous Phase 4
4 Antibodies Phase 4
5 Rho(D) Immune Globulin Phase 4
6 Melanocyte-Stimulating Hormones Phase 4
7 Adrenocorticotropic Hormone Phase 4
8 beta-Endorphin Phase 4
9
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
10
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
11 Sodium Channel Blockers Phase 2
12 Sodium Chloride Symporter Inhibitors Phase 2
13 Amiloride, hydrochlorothiazide drug combination Phase 2
14 Antihypertensive Agents Phase 2
15 diuretics Phase 2
16 Diuretics, Potassium Sparing Phase 2
17
4-Aminopyridine Approved Phase 1 504-24-5 1727
18 Radiopharmaceuticals Phase 1
19
Ocrelizumab Approved, Investigational 637334-45-3
20
rituximab Approved 174722-31-7 10201696
21
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
22
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
23 Micronutrients
24 Trace Elements
25 Vitamins
26 Calcium, Dietary
27 Nutrients
28 Calciferol
29 Antibodies, Monoclonal
30
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
3 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
6 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
7 Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment Completed NCT01056471 Phase 1, Phase 2
8 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
9 Aerobic Exercise to Improve Mobility in Multiple Sclerosis: Optimizing Design and Execution for a Full-scale Multimodal Remyelination Clinical Trial Not yet recruiting NCT04539002 Phase 1, Phase 2
10 Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain Completed NCT00283023 Phase 1
11 A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects Completed NCT02641041 Phase 1
12 A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects Completed NCT03630497 Phase 1 Comparison of BN201 treatment with Placebo
13 Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects Recruiting NCT04699747 Phase 1 F-18 3F4AP
14 Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury Recruiting NCT04710550 Phase 1 F18-3F4AP
15 Monitoring of Neurodegenerative Processes in Children With Multiple Sclerosis by Diffusion-weighed Magnetic Resonance Imaging (DTI) Unknown status NCT02361697
16 Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial Unknown status NCT03610139
17 Determine if the Presence of Characteristic MS-like Lesion(s) on Baseline MRI Predisposes to CIS/MS in Female MZ Twins Discordant for CIS/MS. Completed NCT00617383
18 Pharmacological Recruitment of Endogenous Neural Precursors to Promote Pediatric White Matter Repair: Establishing Correlations Between Visual Outcomes, Saccadic Function and MEG Oscillations in Children With Demyelinating Disorders in Comparison to Healthy Control Children Completed NCT03010826
19 Stimulation of the Human Central and Peripheral Nervous System With a Magnetic Stimulator Completed NCT00001780
20 A Pathologic-MRI Reappraisal of Patients With Atypical Idiopathic Inflammatory Demyelinating Disorders Completed NCT03121105
21 A Registered Cohort Study on Natural Course and Drug Efficacy of Inflammatory Demyelination Disease Recruiting NCT04386018
22 Serum Neurofilaments Light Chain and GFAP (Glial Fibrillary Acidic Protein) in Atypical Idiopathic Inflammatory Demyelinating Disorders Recruiting NCT04201470
23 Efficacy and Safety of Intermittent Bolus Comparing With Traditional Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia at Rajavithi Hospital Recruiting NCT04561531
24 Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions Recruiting NCT03268239
25 Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination Recruiting NCT03268096
26 Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases Active, not recruiting NCT00445367
27 A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™ Active, not recruiting NCT03562975 Ocrelizumab
28 The Clinical Features of Combined Central and Peripheral Demyelination Not yet recruiting NCT04664647
29 Natural History Study of Children With Metachromatic Leukodystrophy Terminated NCT01963650
30 7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases Withdrawn NCT01973517 Feraheme;Gadolinium-based contrast
31 Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection Withdrawn NCT02872506 Anti TNF

Search NIH Clinical Center for Demyelinating Disease

Cochrane evidence based reviews: demyelinating diseases

Genetic Tests for Demyelinating Disease

Anatomical Context for Demyelinating Disease

MalaCards organs/tissues related to Demyelinating Disease:

40
T Cells, Spinal Cord, Brain, B Cells, Bone Marrow, Endothelial, Myeloid

Publications for Demyelinating Disease

Articles related to Demyelinating Disease:

(show top 50) (show all 6870)
# Title Authors PMID Year
1
STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. 61 54
19606498 2010
2
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. 61 54
20033986 2009
3
Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. 61 54
20008665 2009
4
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. 54 61
19938104 2009
5
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. 61 54
19892975 2009
6
[What I have learned and accomplished through research on multiple sclerosis (MS)]. 54 61
20030191 2009
7
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. 61 54
19229993 2009
8
Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. 61 54
19465451 2009
9
The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease. 54 61
19380818 2009
10
Assessment of citrullinated myelin by 1H-MR spectroscopy in early-onset multiple sclerosis. 54 61
19147724 2009
11
[Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis]. 61 54
19363997 2009
12
Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. 54 61
18803324 2008
13
[Neuromyelitis optica and anti-aquaporin 4 antibody--an overview]. 61 54
18516975 2008
14
Polarity development in oligodendrocytes: sorting and trafficking of myelin components. 61 54
18172773 2008
15
Water movements in the brain: role of aquaporins. 61 54
18054802 2008
16
Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. 54 61
18484192 2008
17
Cleavage of myelin associated glycoprotein by matrix metalloproteinases. 61 54
18063113 2008
18
[Neuromyelitis optica]. 61 54
17934711 2007
19
The complex etiology of multiple sclerosis. 61 54
17537409 2007
20
[TNF-alpha inhibitors and demyelinating disease]. 61 54
18062640 2007
21
Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. 54 61
17456525 2007
22
Neuromyelitis optica. 54 61
17495617 2007
23
Crohn's disease: a review of current treatment with a focus on biologics. 61 54
18034589 2007
24
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. 54 61
17294606 2007
25
No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab. 61 54
16606644 2006
26
Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates. 54 61
16903876 2006
27
Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. 54 61
16769867 2006
28
Long term safety of etanercept in elderly subjects with rheumatic diseases. 61 54
16150792 2006
29
Statistical diffusion tensor histology reveals regional dysmyelination effects in the shiverer mouse mutant. 54 61
16213163 2006
30
Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. 61 54
16227104 2005
31
Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. 54 61
15844172 2005
32
NG2-positive cells in CNS function and the pathological role of antibodies against NG2 in demyelinating diseases. 54 61
15949494 2005
33
GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo. 54 61
15781194 2005
34
Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. 54 61
15809314 2005
35
Astroglial-derived lymphotoxin-alpha exacerbates inflammation and demyelination, but not remyelination. 61 54
15382206 2005
36
The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. 61 54
16268663 2005
37
The 14-3-3 protein in multiple sclerosis: a marker of disease severity. 54 61
15471360 2004
38
A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. 61 54
15370396 2004
39
Demyelination and inhibition of tumor necrosis factor (TNF). 54 61
15552527 2004
40
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. 54 61
15268666 2004
41
Increased susceptibility to experimental autoimmune neuritis after upregulation of the autoreactive T cell response to peripheral myelin antigen in apolipoprotein E-deficient mice. 54 61
14989598 2004
42
Safety of tumour necrosis factor-alpha antagonists. 54 61
15061685 2004
43
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. 54 61
15058523 2004
44
Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. 61 54
15219899 2004
45
A combinatorial network of evolutionarily conserved myelin basic protein regulatory sequences confers distinct glial-specific phenotypes. 61 54
14614079 2003
46
Transient exposure to FGF2 enhances myelination in embryonic brain cell cocultures. 61 54
12710930 2003
47
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. 54 61
12620653 2003
48
TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. 61 54
12465041 2003
49
Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. 61 54
12824709 2003
50
Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus. 61 54
12355425 2002

Variations for Demyelinating Disease

Expression for Demyelinating Disease

Search GEO for disease gene expression data for Demyelinating Disease.

Pathways for Demyelinating Disease

Pathways related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF PTPRC MMP9 IL1B IL17A IFNG
2
Show member pathways
13.69 TNF IL1B IL17A IFNG IFNB1 IFNA1
3
Show member pathways
13.55 TNF NTF3 IL1B IL17A IFNG IFNB1
4
Show member pathways
13.33 TNF MMP9 IL1B IL17A IFNG IFNB1
5
Show member pathways
13.32 TNF PTPRC NTF3 IL1B IL17A CXCL10
6
Show member pathways
13.06 TNF MMP9 IL1B IFNG IFNB1 IFNA1
7
Show member pathways
12.87 TNF IL1B IL17A IFNG IFNA1 HLA-DRB1
8 12.83 TNF IL1B IFNG IFNB1 IFNA1 HLA-DRB1
9
Show member pathways
12.75 TNF IL1B IFNG IFNB1 IFNA1 HLA-DRB1
10
Show member pathways
12.62 TNF PTPRC IL1B IL17A IFNG
11
Show member pathways
12.62 TNF IL1B IL17A IFNG HLA-DRB1
12
Show member pathways
12.61 TNF IL1B IL17A IFNG CCL2
13
Show member pathways
12.57 TNF IFNG IFNB1 IFNA1 CXCL10
14 12.37 TNF PTPRC IL1B IL17A IFNG IFNA1
15
Show member pathways
12.34 TNF CXCL10 CCR6 CCL2
16
Show member pathways
12.34 TNF IL1B IFNG CCL2
17 12.29 TNF IL1B IFNB1 IFNA1 CCL2
18
Show member pathways
12.27 TNF IL1B IFNG HLA-DRB1
19
Show member pathways
12.26 TNF IL1B IFNG IFNB1 IFNA1
20
Show member pathways
12.26 TNF NTF3 IL1B IL17A IFNG IFNB1
21
Show member pathways
12.25 TNF MMP9 IL1B IL17A IFNG CXCL10
22
Show member pathways
12.23 TNF IL1B IFNG IFNB1 CXCL10
23 12.21 TNF IL1B IFNG IFNB1 IFNA1 HLA-DRB1
24 12.2 TNF PLP1 IL1B AQP4
25 12.14 TNF MMP9 IL1B IFNG CCL2
26 12.11 TNF IL1B IFNB1 CCL2
27 12.07 TNF IL1B IFNG IFNB1
28 12.01 TNF MMP9 IL1B IL17A CCL2
29 11.93 TNF MMP9 IL1B IFNB1 CXCL10 CCL2
30
Show member pathways
11.82 TNF IL1B IL17A IFNG
31 11.79 NTF3 MOG CSPG4
32 11.77 PTPRC MMP9 HLA-DRB1
33 11.77 TNF IL1B IL17A IFNG HLA-DRB1 CCL2
34
Show member pathways
11.72 TNF MMP9 IL1B IFNG
35 11.72 TNF MMP9 IL1B CCL2
36 11.72 TNF PTPRC IL1B IFNG IFNB1
37 11.61 TNF IL1B IFNG CCL2
38 11.58 TNF IL1B CXCL10 CCL2
39 11.56 TNF IL1B IFNG CCL2
40 11.55 TNF IL1B IFNG
41 11.54 TNF PTPRC IL1B IL17A IFNG CCR6
42 11.52 TNF IL1B IFNG
43 11.42 IL1B IFNG IFNB1 CXCL10
44 11.41 TNF IL1B IFNG
45 11.36 TNF MMP9 MBP IL1B IFNG CXCL10
46 11.34 PTPRC MMP9 CCL2
47 11.34 TNF IL1B IL17A IFNG
48 11.19 MMP9 IL1B IFNG CCL2
49 11.04 TNF NTF3 IL1B IL17A CXCL10 CCL2
50 11.02 TNF IL1B CCL2

GO Terms for Demyelinating Disease

Cellular components related to Demyelinating Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TNF NTF3 MMP9 IL1B IL17A IFNG
2 cell surface GO:0009986 9.8 TNF PTPRC MBP HLA-DRB1 CSPG4 CCR6
3 extracellular space GO:0005615 9.7 TNF NTF3 MMP9 IL1B IL17A IFNG
4 myelin sheath GO:0043209 9.43 PLP1 MPZ MBP
5 external side of plasma membrane GO:0009897 9.23 TNF PTPRC MOG IL17A HLA-DRB1 CXCL10

Biological processes related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.08 IL17A IFNG IFNB1 IFNA1 HLA-DRB1
2 cell surface receptor signaling pathway GO:0007166 10 PTPRC IFNG IFNB1 CXCL10 CCL2
3 cell-cell signaling GO:0007267 9.99 NTF3 IL1B IL17A CXCL10
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 TNF PTPRC HLA-DRB1 CCL2
5 positive regulation of cell migration GO:0030335 9.97 PLP1 NTF3 MMP9 IL1B CXCL10
6 cellular response to lipopolysaccharide GO:0071222 9.95 TNF IL1B CXCL10 CCL2
7 defense response GO:0006952 9.93 TNF IFNB1 IFNA1 CXCL10
8 inflammatory response GO:0006954 9.93 TNF PLP1 IL1B IL17A CXCL10 CCL2
9 response to virus GO:0009615 9.88 TNF IFNG IFNB1 CXCL10
10 defense response to virus GO:0051607 9.88 PTPRC IFNG IFNB1 IFNA1 CXCL10
11 B cell differentiation GO:0030183 9.87 PTPRC IFNB1 IFNA1
12 regulation of insulin secretion GO:0050796 9.86 TNF IL1B IFNG
13 chemokine-mediated signaling pathway GO:0070098 9.85 CXCL10 CCR6 CCL2
14 cellular response to organic cyclic compound GO:0071407 9.85 TNF IL1B CCL2
15 positive regulation of interleukin-1 beta production GO:0032731 9.83 TNF IL17A IFNG
16 positive regulation of protein phosphorylation GO:0001934 9.83 TNF MMP9 IL1B IFNG HLA-DRB1
17 myelination GO:0042552 9.82 PLP1 MPZ MBP
18 positive regulation of phagocytosis GO:0050766 9.81 TNF IL1B IFNG
19 immune response GO:0006955 9.81 TNF MBP IL1B IL17A IFNG HLA-DRB1
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF IL1B IFNG
21 protein kinase B signaling GO:0043491 9.79 TNF IL1B CCL2
22 B cell proliferation GO:0042100 9.77 PTPRC IFNB1 IFNA1
23 activation of MAPK activity GO:0000187 9.77 TNF PTPRC NTF3 IL1B CSPG4
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TNF IL1B CCL2
25 positive regulation of interleukin-6 production GO:0032755 9.72 TNF MBP IL1B IL17A IFNG
26 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
27 positive regulation of osteoclast differentiation GO:0045672 9.7 TNF IL17A IFNG
28 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.69 TNF MBP
29 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
30 macrophage differentiation GO:0030225 9.69 MMP9 IFNG HLA-DRB1
31 positive regulation of NMDA glutamate receptor activity GO:1904783 9.67 IFNG CCL2
32 vascular endothelial growth factor production GO:0010573 9.67 TNF IL1B
33 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.67 IFNG IFNB1 IFNA1
34 axon ensheathment GO:0008366 9.66 PLP1 MBP
35 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.65 TNF PTPRC
36 positive regulation of interleukin-23 production GO:0032747 9.64 IL17A IFNG
37 positive regulation of fever generation GO:0031622 9.64 TNF IL1B
38 sequestering of triglyceride GO:0030730 9.62 TNF IL1B
39 positive regulation of T cell mediated immunity GO:0002711 9.59 PTPRC IL1B
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 TNF IL1B IFNG
41 DN2 thymocyte differentiation GO:1904155 9.56 PTPRC CCR6
42 cytokine-mediated signaling pathway GO:0019221 9.56 TNF MMP9 IL1B IL17A IFNB1 IFNA1
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.55 TNF IFNG
44 positive regulation of nitrogen compound metabolic process GO:0051173 9.54 TNF IFNG
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IL1B IFNG
46 humoral immune response GO:0006959 9.1 TNF IFNG IFNB1 IFNA1 CCR6 CCL2

Molecular functions related to Demyelinating Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 PTPRC NTF3 MOG CXCL10 CCL2
2 cytokine activity GO:0005125 9.23 TNF IL1B IL17A IFNG IFNB1 IFNA1
3 structural constituent of myelin sheath GO:0019911 9.16 PLP1 MBP

Sources for Demyelinating Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....